Icecure Medical (ICCM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IceCure Medical Ltd. has been granted a new U.S. patent for its innovative cryogenic pump technology, expanding the company’s leading position in cryoablation technologies for tumor treatment. With over 50 patents worldwide, this latest patent enhances IceCure’s platform, allowing broader applications in medical procedures and indicating strong potential for future growth. The company’s advanced cryoablation systems, including the flagship ProSense system, offer a minimally invasive alternative for tumor removal and are sold globally.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.